Analyst Ratings For Amgen, Inc. (NASDAQ:AMGN)
Today, Oppenheimer set its price target on Amgen, Inc. (NASDAQ:AMGN) to $224.00 per share.
There are 12 Hold Ratings, 10 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Amgen, Inc. (NASDAQ:AMGN) is Hold with a consensus target price of $204.7277 per share, a potential 1.43% downside.
Some recent analyst ratings include
- 10/1/2018-Amgen, Inc. (NASDAQ:AMGN) had its Buy rating reiterated by Cann with a $224.00 price target
- 10/1/2018-Amgen, Inc. (NASDAQ:AMGN) had its Buy rating reiterated by Jefferies Financial Group with a $220.00 price target
- 10/1/2018-Amgen, Inc. (NASDAQ:AMGN) has coverage initiated with a Neutral ➝ Neutral rating and $223.00 price target
- 8/29/2018-Amgen, Inc. (NASDAQ:AMGN) had its Neutral rating reiterated by Wells Fargo & Co with a $197.00 price target
Recent Insider Trading Activity For Amgen, Inc. (NASDAQ:AMGN)
Amgen, Inc. (NASDAQ:AMGN) has insider ownership of 0.27% and institutional ownership of 82.48%.
- On 7/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $195.71 per share and the total transaction amounting to $298,457.75.
- On 6/12/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $184.27 per share and the total transaction amounting to $281,011.75.
- On 5/14/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $174.10 per share and the total transaction amounting to $265,502.50.
- On 4/12/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $172.68 per share and the total transaction amounting to $263,337.00.
- On 3/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $189.75 per share and the total transaction amounting to $289,368.75.
- On 2/14/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $174.18 per share and the total transaction amounting to $265,624.50.
- On 1/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $185.62 per share and the total transaction amounting to $283,070.50.
About Amgen, Inc. (NASDAQ:AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; and The University of Texas MD Anderson Cancer Center. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Recent Trading Activity for Amgen, Inc. (NASDAQ:AMGN)
Shares of Amgen, Inc. closed the previous trading session at 207.85 up +0.94 0.45% with 208.1 shares trading hands.